FDA Clears CAPLYTA® as New Adjunctive Therapy for Depression
Titusville, New Jersey – November 6, 2025 – Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and...
patient outcomes
Advertisement
AbbVie Raises 2025 Outlook as Skyrizi and Rinvoq Surge
NORTH CHICAGO, Ill., November 2, 2025 — AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical leader, has raised its annual...
TREMFYA® Shows 96-Week Remission in Crohn’s Disease with Fully Subcutaneous Regimen
Phoenix, AZ | October 27, 2025 – Johnson & Johnson’s TREMFYA® (guselkumab) becomes the first and only IL-23 inhibitor...
FDA Approves TEZSPIRE for Chronic Rhinosinusitis with Nasal Polyps
THOUSAND OAKS, Calif., October 17, 2025 — In a landmark regulatory decision, the U.S. Food and Drug Administration (FDA)...
BrainBox TBI Study Reveals Breakthrough in Concussion Diagnosis
RICHMOND, VA – October 17, 2025: BrainBox Solutions has published a major analysis in JAMA Network OPEN from its...
Advertisements
Privo Technologies Completes Phase 2 Run-In for PRV111 Oral Cancer Patch
PEABODY, Mass., Oct. 14, 2025 — Privo Technologies, Inc., a clinical-stage biopharmaceutical company pioneering localized cancer therapies, announced the...
NEXTBIOMEDICAL Launches U.S. Pivotal Trial for Nexsphere-F™ in Knee OA
SEOUL, South Korea, Oct. 13, 2025 — NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), a South Korea-based innovative medical device company,...
Johnson & Johnson Launches CORE-VA Registry to Advance Arrhythmia Care
IRVINE, Calif., October 10, 2025 — Johnson & Johnson MedTech has announced the launch of the CORE-VA (Catheter-based Outcomes...
Merck Reports Positive HYPERION Results for Pulmonary Hypertension Therapy
RAHWAY, N.J., Sept. 30, 2025 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today...
Oncolytics Prepares Registration Trial in First-Line Pancreatic Cancer
SAN DIEGO, Sept. 29, 2025 — Oncolytics Biotech® Inc. (NASDAQ: ONCY) today announced a key update on its plan...